(July 14, 2017, 10:41 AM EDT) -- ALEXANDRIA, Va. — In a July 10 petition for post-grant review (PGR), a pharmaceutical company and a limited liability company that bills itself as a “partner” in inter partes review proceedings alleged that a patent covering an oral, liquid lisinopril formulation should not have been issued (KVK-Tech Inc., et al. v. Silvergate Pharmaceuticals Inc., No. PGR2017-00039, PTAB)....